Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 3/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 11/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606109 | 1.00 | PLA2G2A (0.50) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL19322708 | 0.89 | PLA2G2A (0.53) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL19322668 | 0.89 | PLA2G2A (0.53) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL11302097 | 0.86 | TLR2 (0.49) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL11299863 | 0.86 | TLR2 (0.49) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL11299859 | 0.86 | TLR2 (0.49) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL16475725 | 0.86 | TLR2 (0.49) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL16475732 | 0.86 | TLR2 (0.49) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL11302100 | 0.86 | TLR2 (0.49) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL18512617 | 0.84 | PLA2G2A (0.54) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742661-A2 | LIPID COMPOSITIONS AND USE THEREOF | Neopharm, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20050277611-A1 | Cationic cardiolipin analoges and its use thereof | NEOPHARM, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| EP-1558562-A1 | CATIONIC CARDIOLIPIN ANALOGS AND USE THEREOF | Neopharm, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005067632-A2 | LIPID COMPOSITIONS AND USE THEREOF | NEOPHARM, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2004035523-A1 | CATIONIC CARDIOLIPIN ANALOGS AND USE THEREOF | NEOPHARM, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277611-A1 | Cationic cardiolipin analoges and its use thereof | LCLAT1, CETP, LIPA | PLA2G2A 90/4885PLA2G10 118/4885PLA2G1B 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.